



FOR IMMEDIATE RELEASE:

Contact: CynTellect
Jim Linton, Ph.D.
Chief Business Officer
Phone: (858) 450-7060
jlinton@cynTellect.com

**CynTellect Appoints Drs. Alan Aderem, Charles Cantor and Michael Hanley
to Its Scientific Advisory Board**

*New members to foster expanded applications of cell-based manipulation
from functional proteomics to stem cells*

San Diego, CA – January 24, 2007 – CynTellect, Inc., a privately-held biotechnology company, today announced that it has appointed Drs. Alan Aderem, Charles Cantor and Michael Hanley to its Scientific Advisory Board (SAB). These three world-renowned scientists along with the company's scientific founder, Dr. Bernhard Palsson, form an industry-seasoned SAB composed of scientific thought-leaders to foster new, innovative and commercially-relevant applications of the company's laser-based live cell manipulation technology.

“With the successful launch of our LEAP system in 2006, we are now moving aggressively to explore and develop new applications that will further enhance the value of cellular science in the research laboratory, as well as additional applications in bioprocessing, stem cell processing and microgenomics,” stated Fred Koller, Ph.D., President and Chief Technology Officer of CynTellect. “We are very pleased to add three such well-respected scientists to our SAB as they offer CynTellect a unique and valuable asset – proven scientific creativity to fuel innovation blended with industry experience to assess the viability of such commercial opportunities.”

Dr. Alan Aderem is the Director of the Institute for Systems Biology which he co-founded with Drs. Leroy Hood and Rudy Aebersold. He is an internationally-recognized immunologist and cell biologist and his current focus is the innate immune system – the body's first line of defense against infection. Prior to co-founding the ISB, Dr. Aderem was a faculty member at the University of Washington. Before that, he headed the Laboratory of Signal Transduction at The Rockefeller University. He has received numerous awards and honors including a MERIT Award from the National Institute of Allergy and Infectious Diseases, a Pew Scholars award, and awards from the Burroughs Welcome Trust, the American Heart Association, and the Gates Foundation. Dr. Aderem has published over 150 peer reviewed manuscripts and received his Ph.D. degree in biophysics and biology from the University of Cape Town in South Africa.

Dr. Charles Cantor is the Chief Scientific Officer of Sequenom and Chairman of its Scientific Advisory Board. In May 2000, Dr. Cantor was appointed to Sequenom's Board of Directors. Previously, he was the Chair and Professor of the Department of Biomedical Engineering, and Director of the Center for

Advanced Biotechnology at Boston University. Dr. Cantor also held positions at Columbia University and the University of California, Berkeley. He was also the Director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory. A world-renowned scientist, Dr. Cantor is a consultant to more than 16 biotech firms, has published more than 400 peer reviewed articles, been granted 54 U.S. patents and co-authored a three-volume textbook on genomics entitled, **“Genomics: The Science and Technology of the Human Genome Project.”**

Dr. Michael Hanley is currently Vice President, Discovery Research at Amylin Pharmaceuticals in San Diego, California. Prior to joining Amylin, Dr. Hanley held senior faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis. Dr. Hanley has served on advisory and review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. Prior to joining Amylin, Dr. Hanley was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Dr. Hanley has published more than 160 peer reviewed articles and he received his B.S. in Biochemistry and his Ph.D. in Molecular Biology from the University of California, Berkeley.

About Cynlect

Cynlect, Inc. is a biotechnology company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at www.cynlect.com.

* * * * *